81 related articles for article (PubMed ID: 18094430)
1. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
[TBL] [Abstract][Full Text] [Related]
2. Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword?
Tarazona R; Casado JG; Soto R; DelaRosa O; Peralbo E; Rioja L; Peña J; Solana R
Cancer Immunol Immunother; 2004 Oct; 53(10):911-24. PubMed ID: 15127235
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.
Cordova A; Toia F; La Mendola C; Orlando V; Meraviglia S; Rinaldi G; Todaro M; Cicero G; Zichichi L; Donni PL; Caccamo N; Stassi G; Dieli F; Moschella F
PLoS One; 2012; 7(11):e49878. PubMed ID: 23189169
[TBL] [Abstract][Full Text] [Related]
4. Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors.
Park JH; Kim HJ; Kim CW; Kim HC; Jung Y; Lee HS; Lee Y; Ju YS; Oh JE; Park SH; Lee JH; Lee SK; Lee HK
Nat Immunol; 2021 Mar; 22(3):336-346. PubMed ID: 33574616
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism.
Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Adv Sci (Weinh); 2021 Nov; 8(21):e2101029. PubMed ID: 34486239
[TBL] [Abstract][Full Text] [Related]
6. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
[TBL] [Abstract][Full Text] [Related]
7. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
Anichini A; Vegetti C; Mortarini R
Cancer Immunol Immunother; 2004 Oct; 53(10):855-64. PubMed ID: 15175905
[TBL] [Abstract][Full Text] [Related]
8. Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy.
Banerjee A; Li D; Guo Y; Mahgoub B; Paragas L; Slobin J; Mei Z; Manafi A; Hata A; Li K; Shi L; Westwick J; Slingluff C; Lazear E; Krupnick AS
J Immunol; 2021 Jul; 207(1):333-343. PubMed ID: 34155069
[TBL] [Abstract][Full Text] [Related]
9. Identification of T cell clones without the need for sequencing.
Martinez RJ; Neeld DK; Evavold BD
J Immunol Methods; 2015 Sep; 424():28-31. PubMed ID: 25960175
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
11. Regulation of NKG2D
Hu J; Batth IS; Xia X; Li S
Oncoimmunology; 2016; 5(12):e1252012. PubMed ID: 28123894
[TBL] [Abstract][Full Text] [Related]
12. NKG2D ligands as therapeutic targets.
Spear P; Wu MR; Sentman ML; Sentman CL
Cancer Immun; 2013; 13():8. PubMed ID: 23833565
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
15. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection.
Chang YT; Wu CC; Shyr YM; Chen TC; Hwang TL; Yeh TS; Chang KP; Liu HP; Liu YL; Tsai MH; Chang YS; Yu JS
PLoS One; 2011; 6(5):e20029. PubMed ID: 21625447
[TBL] [Abstract][Full Text] [Related]
16. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients.
Di Tomaso T; Mazzoleni S; Wang E; Sovena G; Clavenna D; Franzin A; Mortini P; Ferrone S; Doglioni C; Marincola FM; Galli R; Parmiani G; Maccalli C
Clin Cancer Res; 2010 Feb; 16(3):800-13. PubMed ID: 20103663
[TBL] [Abstract][Full Text] [Related]
17. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.
Riond J; Rodriguez S; Nicolau ML; al Saati T; Gairin JE
Cancer Immun; 2009 Nov; 9():10. PubMed ID: 19877577
[TBL] [Abstract][Full Text] [Related]
18. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.
Casado JG; Pawelec G; Morgado S; Sanchez-Correa B; Delgado E; Gayoso I; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2009 Sep; 58(9):1517-26. PubMed ID: 19259667
[TBL] [Abstract][Full Text] [Related]
19. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
